key: cord-0962558-41amnz2b
authors: Willems, L.H.; Nagy, M.; ten Cate, H.; Spronk, H.M.H.; Groh, L.A.; Leentjens, J.; Janssen, N.A.F.; Netea, M.G.; Thijssen, D.H.J.; Hannink, G.; van Petersen, A.S.; Warlé, M.C.
title: Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19
date: 2021-12-04
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.11.027
sha: 850667da0f6eb85e6449c3232ab3668e4d6dea1e
doc_id: 962558
cord_uid: 41amnz2b

INTRODUCTION: Endothelial damage and thrombosis caused by COVID-19 may imperil cardiovascular health. More than a year since the WHO declared COVID-19 pandemic, information on its effects beyond the acute phase is lacking. We investigate endothelial dysfunction, coagulation and inflammation, 3 months post-COVID-19. MATERIALS AND METHODS: A cohort study was conducted including 203 patients with prior COVID-19. Macrovascular dysfunction was assessed by measuring the carotid artery diameter in response to hand immersion in ice-water. A historic cohort of 312 subjects served as controls. Propensity score matching corrected for baseline differences. Plasma concentrations of endothelin-1 were measured in patients post-COVID-19, during the acute phase, and in matched controls. Coagulation enzyme:inhibitor complexes and inflammatory cytokines were studied. RESULTS AND CONCLUSIONS: The prevalence of macrovascular dysfunction did not differ between the COVID-19 (18.6%) and the historic cohort (22.5%, RD −4%, 95%CI: −15–7, p = 0.49). Endothelin-1 levels were significantly higher in acute COVID-19 (1.67 ± 0.64 pg/mL) as compared to controls (1.24 ± 0.37, p < 0.001), and further elevated 3 months post-COVID-19 (2.74 ± 1.81, p < 0.001). Thrombin:antithrombin(AT) was high in 48.3%. Markers of contact activation were increased in 16–30%. FVIIa:AT (35%) and Von Willebrand Factor:antigen (80.8%) were elevated. Inflammatory cytokine levels were high in a majority: interleukin(IL)-18 (73.9%), IL-6 (47.7%), and IL-1ra (48.9%). At 3 months after acute COVID-19 there was no indication of macrovascular dysfunction; there was evidence, however, of sustained endothelial cell involvement, coagulation activity and inflammation. Our data highlight the importance of further studies on SARS-CoV-2 related vascular inflammation and thrombosis, as well as longer follow-up in recovered patients.

Coronavirus disease 2019 (COVID- 19) results from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), preferentially affecting the upper airways and pulmonary system. 1 Depending on the severity of infection, dissemination towards multiple other organs occurs and systemic COVID-19 is associated with a high incidence of thromboembolic complications and risk of multi-organ failure. [2] [3] [4] Endothelial vascular injury and thrombo-inflammation are emerging key factors in COVID-19 pathophysiology. [5] [6] [7] [8] Pronounced endothelial cell damage was found in COVID-19 autopsy studies 5 , and markers of endothelial cell activation are significantly increased in severe COVID-19 9 and associated with organ damage, including liver, heart and brain 10 . This endothelial cell activation and dysfunction may be aggravated by the interplay of thrombo-inflammatory mediators and cells, including neutrophils that trigger contact and complement activation, perturbing the barrier function and contributing to thrombosis and cardiovascular disease. 11

Severe COVID-19 occurs more often in subjects with established cardiovascular disease or in those with cardiovascular risk factors. 4, 12 Notably, all factors associated with worse disease outcome, such as cardiovascular disease, higher age, obesity, hypertension and diabetes, also predispose to endothelial dysfunction. [13] [14] [15] [16] [17] In different cohorts of cardiovascular patients without COVID-19, the presence of endothelial dysfunction is strongly related to the occurrence of cardiovascular events, including stroke, myocardial infarction and limb events. [18] [19] [20] Although it has been more than a year since the WHO declared COVID-19 a global pandemic, there is a paucity of information related to the effects of COVID-19 on the cardiovascular system beyond the acute phase. 21 Moreover, the SARS-Cov-2 pandemic represents a tremendous health problem including the frequent occurrence of often unexplained J o u r n a l P r e -p r o o f Journal Pre-proof prolonged complaints and morbidity long after the acute infection (so-called "long COVID" 22 ). We hypothesize that sustained inflammation, coagulation activation and endothelial cell activation may ultimately lead to macrovascular dysfunction with an increased risk for developing cardiovascular complications later on. 11 Therefore, we firstly investigated whether macrovascular dysfunction could be observed 3 months after recovery from acute COVID-19. Furthermore, we determined whether signs of endothelial cell activation 9,23-25 , coagulation system activation 26 , and circulating inflammatory cytokines 9,27-28 , as observed during the acute phase, are present 3 months after recovery from acute COVID-19 symptoms.

COVAS was a cross-sectional observational cohort study, initiated at Radboudumc (Nijmegen, the Netherlands) and conducted at Bernhoven hospital (Uden, the Netherlands).

The study was approved by the regional ethics committee Arnhem-Nijmegen (reference number NL74101.091.20), and local approval has been obtained of the local directory boards. This study was conducted in accordance with the latest revision of the Declaration of Helsinki. Data available on request from the authors.

Prespecified risk factors for endothelial dysfunction were age 13 , sex 32 , body mass index (BMI) 14 , smoking status 33 , atherosclerotic cardiovascular disease 15 , hypertension 16 , hyperlipidaemia 34 and diabetes mellitus 17 . Subjects were either healthy volunteers, patients with cardiovascular risk factors or patients with symptomatic cardiovascular disease.

Incomplete case files were excluded from final analyses. Propensity score matching was used to select individuals, based on baseline characteristics and cardiovascular risk profile, to match those with COVID-19.

Measurement of endothelin-1, coagulation and inflammatory cytokines:

Whole blood of recovered COVID-19 patients was collected by venipuncture in Lithium-Heparin (Vacuette) tubes. Platelet poor plasma was prepared by centrifuging whole blood at 2500g for 10 min followed by a second centrifugation step at 2500g for 20 min, both at room temperature. Subsequently, platelet poor plasma was snap frozen and stored at -80°C until infection. Plasma concentrations below the lower detection limit were set on the lowest detectable value.

The primary endpoint was the prevalence of macrovascular dysfunction, defined as a constrictive response to the CAR test in the COVAS cohort compared to the historic control cohort. 29 The CAR response was either a dilatory or a constrictive reaction, dichotomized by an area under the curve of at least zero or below zero, respectively. The secondary endpoint was the plasma concentration of ET-1 in the COVAS cohort compared to the acute phase and matched controls.

This study was designed to detect a 2.5-fold excess risk of macrovascular dysfunction in the COVAS cohort compared to the matched historic control cohort. With a power of 0.8 and an alpha of 5%, 97 patients with COVID-19 infection were required. Assuming an acceptable match rate of 50%, the final sample size was set on 200 participants.

For the CAR test, propensity score matching (PSM) was applied to correct for systematic differences in baseline characteristics that could influence endothelial function (i.e. age, sex, BMI, smoking status, atherosclerotic cardiovascular disease, hypertension, hyperlipidemia and diabetes) between post-COVID-19 patients and historic controls. The propensity score is defined as the chance to be in the COVAS cohort, based on baseline characteristics.

Propensity score was estimated using logistic regression analysis with the group (COVAS or J o u r n a l P r e -p r o o f Journal Pre-proof historic control) as dependent variable in relation to baseline characteristics. The balance in covariates was evaluated using standardized mean differences (SMD), where a SMD of 0.1 indicates a negligible correlation. 36 After PSM, univariable logistic regression analysis was performed to estimate the difference in CAR response and value between the historic control cohort and the COVAS cohort.

ET-1 levels of the COVAS cohort were compared to matched controls using the Mann-Whitney U test. Sub-analyses were performed on patients with preserved blood plasma during the acute phase of infection to compare ET-1 concentrations of the acute phase with ET-1 concentrations post-COVID-19.

Blood plasma markers of coagulation activation and inflammatory cytokines were presented as mean ± standard deviation (SD) and the proportion of patients with concentrations above normal range. Normal ranges of in-house developed ELISA methods were defined as above normal mean + 1 SD (based on previous validation studies 35 

The mean age at COVID-19 diagnosis was 62.7 years and 63.5% of the patients were male ( Figure 3 ). In vivo coagulation activity was measured in the post-COVID-19 cohort and increased coagulation activity was observed in patients 6-20 weeks after recovery of acute COVID-19 (Table 2) 

A heatmap of correlations between markers of endothelial dysfunction, markers of coagulation and inflammatory cytokines is presented in Figure 4 . 

This study is, to our best knowledge, the first to investigate macrovascular dysfunction, This contact pathway could contribute to PAR2 activation 44 , and lead to the secretion of IL-1 family cytokines by monocytes 45 

Based on this unique design, we found evidence of sustained endothelial cell activation, coagulation activation and inflammation. However, these changes did not coincide with macrovascular dysfunction, 3 months after acute COVID-19. Our data highlight the importance of further studies on SARS-CoV-2 related coagulation activation and vascular inflammation, with longer follow-up periods in recovered patients, with the newly raised hypothesis of IL-1 family cytokines, IL-18 in particular, induced arterial inflammation.

Sustained endothelial activation as reflected by high ET-1 levels could be maintained by contact pathway activation, possibly induced through PAR1 stimulation. Future studies

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

J o u r n a l P r e -p r o o f Journal Pre-proof 

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad

Viral Coagulopathy in Patients With COVID-19: Treatment and Care

Vascular Endothelial Damage in the Pathogenesis of Organ Injury in Severe COVID-19

ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association. Cardiovascular biomarkers in patients with COVID-19

Clinical characteristics of Coronavirus disease 2019 in China

Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women

Body Mass Index Is Associated With Microvascular Endothelial Dysfunction in Patients With Treated Metabolic Risk Factors and Suspected Coronary Artery Disease

Endothelial function: cardiac events

Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension

Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus

Endothelial dysfunction: a marker of atherosclerotic risk

Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease

Prognostic significance of endothelial dysfunction in hypertensive patients

Urgent Need for Studies of the Late Effects of SARS-CoV-2 on the Cardiovascular System

Post-acute COVID-19 syndrome

Circulating endothelial cells as a marker of endothelial injury in severe COVID-19

Endothelial cell infection and endotheliitis in COVID-19

Microvascular dysfunction in COVID-19: the MYSTIC study

Neutrophils and Contact Activation of Coagulation as Potential Drivers of COVID-19

Role for anti-cytokine therapies in severe coronavirus disease 2019

IL-18 and infections: is there a role for targeted therapies?

Carotid Artery Reactivity Predicts Events in Peripheral Arterial Disease Patients

Correlation of carotid artery reactivity with cardiovascular risk factors and coronary artery vasodilator responses in asymptomatic, healthy volunteers

Similarity between carotid and coronary artery responses to

Sex differences in endothelial function important to vascular health and overall cardiovascular disease risk across the lifespan

Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes

The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients

ten Cate H. The plasma kallikrein-kinin system and risk of cardiovascular disease in men

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography

Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge

Coagulopathy in COVID-19

Protease activated receptors: theme and variations

Heterogeneous mechanisms of endothelium-dependent relaxation for thrombin and peptide activators of protease-activated receptor-1 in porcine isolated coronary artery

Concentration dependent dual effect of thrombin in endothelial cells via Par-1 and Pi3 Kinase

The hemostatic system as a modulator of atherosclerosis

Factor Xa induces proinflammatory cytokine expression in RAW 264.7 macrophages via protease-activated 14

Interleukin 18 and coronary heart disease: prospective study and systematic review

Thrombin Generation and Atherothrombosis: What Does the Evidence Indicate?

Endothelial dysfunction in COVID-19: current findings and therapeutic implications

Systemic microvascular endothelial dysfunction and disease severity in COVID-19 patients: Evaluation by laser Doppler perfusion monitoring and cytokine/chemokine analysis